Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2026)
Denali Therapeutics (DNLI) reported Income from Continuing Operations of 128447000.0 for Q1 2026, up 3.4% year-over-year from 124221579.21 in Q1 2025, and little changed quarter-over-quarter from 128447000.0 in Q4 2025.
Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 10 years of Income from Continuing Operations data on file, last reported at 128447000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 128447000.0, up 3.4% year-over-year; the trailing twelve-month figure through Mar 2026 was 507915000.0 (down 11.91% YoY), and the FY2025 annual result was 512540000.0, down 21.23% from the prior year.
- Income from Continuing Operations was little changed at 128447000.0 in Q1 2026 per DNLI's latest filing, from 128447000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 183383000.0 in Q2 2023 and troughed at 132970000.0 in Q1 2025.
- A 5-year average of 90357823.53 and a median of 107192000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations jumped 411.91% in 2023, then tumbled 154.0% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 98678000.0 in 2022, then slipped by 21.07% to 119473000.0 in 2023, then rose by 4.01% to 114685000.0 in 2024, then fell by 12.0% to 128447000.0 in 2025, then changed by 0.0% to 128447000.0 in 2026.
- Business Quant data shows DNLI's Income from Continuing Operations at 128447000.0 in Q1 2026, 128447000.0 in Q4 2025, and 126902000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | -128.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.45 Mn |
| Dec 31, 2025 | -128.45 Mn |
| Sep 30, 2025 | -126.90 Mn |
| Jun 30, 2025 | -124.12 Mn |
| Mar 31, 2025 | -132.97 Mn |
| Dec 31, 2024 | -114.69 Mn |
| Sep 30, 2024 | -107.19 Mn |
| Jun 30, 2024 | -99.03 Mn |
| Mar 31, 2024 | -101.80 Mn |
| Dec 31, 2023 | -119.47 Mn |
| Sep 30, 2023 | -99.35 Mn |
| Jun 30, 2023 | 183.38 Mn |
| Mar 31, 2023 | -109.78 Mn |
| Dec 31, 2022 | -98.68 Mn |
| Sep 30, 2022 | -103.30 Mn |
| Jun 30, 2022 | -58.79 Mn |
| Mar 31, 2022 | -66.50 Mn |
| Dec 31, 2021 | -75.26 Mn |
| Sep 30, 2021 | -84.59 Mn |
| Jun 30, 2021 | -60.69 Mn |